RESUMO
Nail plate brittleness (or fragility) is a common complaint affecting up to 20% of the population, especially women over 50 years of age, with fingernail fragility being more prevalent than toenail fragility. Nail brittleness is characterized by nails that split, flake and crumble, become soft and lose elasticity. The main clinical presentations are: onychoschizia, onychorrhexis, superficial granulation of keratin and worn-down nails. According to causative factors, we can distinguish 2 forms of nail fragility (NF): a primary "idiopathic or brittle nail syndrome" form and NF secondary to different causes such as inflammatory nail disorders, infections, systemic diseases and general conditions, traumas and alteration of the nail hydration. Optimal management requires treatment of the primary cause of brittle nails, when possible. In idiopathic NF oral supplementation, vitamins (especially biotin, also known as vitamin B7), trace elements and amino acids (especially cysteine) have been reported to be useful. In addition, several products, such as topical moisturizers and lacquers could be considered to restructure the affected nail plate and to reduce psychological impacts of this common problem.
RESUMO
Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophyte molds, and yeasts. This difficult-to-treat chronic infection has a tendency to relapse despite treatment. This paper aims to offer a global perspective on onychomycosis management from expert physicians from around the world. Overall, the majority of experts surveyed used systemic, topical, and combination treatments approved in their countries and monitored patients based on the product insert or government recommendations. Although the basics of treating onychomycosis were similar between countries, slight differences in onychomycosis management between countries were found. These differences were mainly due to different approaches to adjunctive therapy, rating the severity of disease and use of prophylaxis treatment. A global perspective on the treatment of onychomycosis provides a framework of success for the committed clinician with appreciation of how onychomycosis is managed worldwide.
Assuntos
Antifúngicos/uso terapêutico , Dermatoses do Pé/terapia , Saúde Global , Onicomicose/terapia , Administração Oral , Administração Tópica , Antifúngicos/farmacologia , Arthrodermataceae/isolamento & purificação , Arthrodermataceae/patogenicidade , Ensaios Clínicos como Assunto , Comorbidade , Interações Medicamentosas , Dermatoses do Pé/epidemiologia , Dermatoses do Pé/microbiologia , Carga Global da Doença , Humanos , Terapia com Luz de Baixa Intensidade/métodos , Onicomicose/epidemiologia , Onicomicose/microbiologia , Fotoquimioterapia/métodos , Prevalência , Recidiva , Tinha dos Pés/tratamento farmacológico , Tinha dos Pés/epidemiologia , Resultado do Tratamento , Leveduras/isolamento & purificação , Leveduras/patogenicidadeAssuntos
Medicina Tradicional , Paroniquia/prevenção & controle , Equipamento de Proteção Individual , Dermatite Ocupacional/etiologia , Dermatite Ocupacional/prevenção & controle , Equipamentos Descartáveis , Dedos , Humanos , Imersão/efeitos adversos , Irritantes/efeitos adversos , Paroniquia/etiologiaRESUMO
A 28-year-old male with histologically proven psoriasis vulgaris was administered oral 8-methoxypsoralen UVA therapy (PUVA). The plaques of psoriasis gradually responded to treatment, however numerous pruritic, violaceous papules over the right forearm and left thigh developed 5 months after starting PUVA (45 sittings with a cumulative dose of 156 J/cm(2)). Histopathologic examination of these lesions was compatible with the diagnosis of lichen planus (LP). On stopping PUVA therapy, the lesions subsided in one month. This case emphasizes the hypothesis that cell injury caused by PUVA therapy could expose some sequestered antigens to autoreactive lymphocytes and induce lichen planus.